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ABSTRACT 
Background: There is a paucity of data on extraintestinal manifestations (EIM) and their 
treatment in pediatric patients with inflammatory bowel disease (IBD).  
Methods: Since 2008, the Pediatric Swiss IBD Cohort Study has collected data on the pediatric 
IBD population in Switzerland. Data on 329 patients were analyzed retrospectively.  
Results: 55 patients (16.7%) suffered from 1-4 EIM (39 Crohn`s disease, 12 ulcerative colitis 
and 4 IBD-Unclassified (IBD-U) patients). At IBD onset, presence of EIM was more frequent 
than in the adult population (8.5% vs. 5.0%, p=0.014). EIM were more frequent in CD when 
compared to UC/IBD-U (22.5 vs. 10.3%, p=0.003). The most prevalent EIM were peripheral 
arthritis (26/329, 7.9%) and aphthous stomatitis (24/329, 7.3%). 27.6% of all EIM appeared 
before IBD diagnosis. Median time between IBD diagnosis and occurrence of first EIM was 1 
month (-37.5 – 149.0). 31 of the 55 patients (56.4%) were treated with one or more anti-TNF 
agents. IBD patients with EIM were more likely to be treated with anti-TNF compared to those 
without (56.4% vs. 35.0%, p=0.003). Response rates to anti-TNF depended on underlying EIM 
and were best for peripheral arthritis (61.5%) and uveitis (66.7%).  
Conclusions: In a cohort of pediatric IBD patients, EIM were frequently encountered. In up to 
30%, EIM appeared before IBD diagnosis. Knowledge of these findings might translate into an 
increased awareness of underlying IBD, thereby decreasing diagnostic delay. Anti- TNF for the 
treatment of certain EIM is effective although a substantial proportion of new EIM might present 
despite ongoing anti-TNF therapy. 
Keywords: extraintestinal manifestations, inflammatory bowel disease, arthritis, uveitis, anti-
TNF 
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What is known: 
‐ Extraintestinal manifestations (EIM) are frequently observed in adult patients with 
inflammatory bowel disease (IBD) 
‐ Little is known about EIM in the pediatric IBD population 
 
What is new: 
‐ EIM are common in pediatric patients with IBD 
‐ Epidemiology and presentation of EIM seem to be similar in the pediatric and adult IBD 
population 
‐ In up to 30% of those patients presenting with EIM, EIM appear before IBD diagnosis 
‐ Type of EIM might affect the responses to anti-TNF. Best rates were seen for peripheral 
arthritis and uveitis 
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INTRODUCTION 
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the gastrointestinal 
tract and can be classified into the two main subtypes Crohn`s disease (CD) and ulcerative colitis 
(UC) (1). As IBD are systemic diseases, which can involve multiple organ systems, 
extraintestinal manifestations (EIM) are frequently observed affecting up to 50% of the adult 
IBD population (2-6). In a non-negligible proportion, EIM appear even before IBD diagnosis is 
established (7). While some reviews broaden the concept of EIM to non-IBD specific 
autoimmune disorders such as thyroid disease or vitiligo and IBD-related complications such as 
osteopathy or nephrolithiasis, the typical EIM involve the following four organs: skin (erythema 
nodosum (EN), pyoderma gangrenosum (PG), psoriasis, aphthous stomatitis), joints (peripheral 
arthritis, axial arthropathy), biliary tract (primary sclerosing cholangitis (PSC)) and eyes (uveitis) 
(7). Most of EIM parallel intestinal disease activity (8-12), are more common in CD than UC and 
are more frequently observed with longer IBD duration (13). In addition, up to one quarter 
presents with more than one EIM (8). Morbidity and mortality are considerably affected (14, 15). 
Although pathogenesis remains mostly elusive, intestinal and extraintestinal IBD seem to share 
TNF-dependent mechanisms (16) and several studies and case reports were able to demonstrate 
beneficial effect of anti-TNF treatments (17-23). However, EIM (such as arthritis and 
paradoxical psoriasiform reactions) can also resemble side effects of anti-TNF therapy (25).  
 
While knowledge of prevalence, appearance and possible treatment options for EIM in adults is 
increasing, it is still limited in the pediatric IBD population. Recent studies have shown higher 
rates of EIM at IBD onset compared to adults with peripheral arthritis and aphthous stomatitis 
being the most prevalent (26, 27). To our knowledge, so far no study has addressed the 
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chronological order of EIM appearance in respect to IBD diagnosis or the influence of anti-TNF 
treatment on the evolution and development of EIM in a pediatric IBD cohort. Given this paucity 
of data, we aimed to assess the frequency and type of EIM, chronological order of appearance of 
EIM and the use of and response to anti-TNF treatment in the Pediatric Swiss IBD Cohort Study 
(PSIBDCS).  
 
METHODS 
Patients 
The Pediatric Swiss IBD Cohort Study (PSIBDCS) is a nationwide sub-study of the Swiss IBD 
cohort study (SIBDCS) including all regions of Switzerland (28). Enrollment started in 2008. 
The SIBDCS and its sub-study are supported by the Swiss National Science Foundation and are 
approved by the local ethics committees of the participating centers. Patients are included in the 
PSIBDCS if they are 18 years old or younger. Additional inclusion criteria and regular 
assessment scheme (baseline and annual follow-up questionnaires) have been discussed 
elsewhere (29). Patients were recruited at University Hospitals, community hospitals and large 
private practices throughout Switzerland. A total of 329 pediatric patients are currently included. 
All 329 patients were retrospectively analyzed for the purpose of this study. 
 
Definition of EIM and anti-TNF outcome 
All EIM had to be diagnosed by clinical experts: Diagnosis of skin manifestations was 
established by a dermatologist, joint affections by a rheumatologist, eye manifestations by an 
ophthalmologist and PSC by a gastroenterologist.  We analyzed the following EIM: peripheral 
arthritis, uveitis, PG, EN, aphthous stomatitis, axial arthropathy, psoriasis and PSC. Diagnosis of 
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EIM relied on previously published criteria (7, 26, 30). We did not consider anemia, glaucoma 
and pancreatic involvement as EIM because it may also be considered as complication of IBD 
therapy (26). Evolution of EIM under anti-TNF treatment was judged according to the 
physician`s global assessment, which was based on patient history and clinical findings. This 
anti-TNF response was classified into the following three categories: clinical improvement, 
stable disease course unaffected by anti-TNF treatment, and clinical worsening.  
 
Data collection and management 
Completed patient and physician questionnaires (baseline and annual follow-up) were sent to the 
datacenter of the SIBDCS located at the Institute of Social and Preventive Medicine, University 
of Lausanne, Switzerland, where data were validated by the responsible data manager and finally 
entered into a Microsoft Access database (Access 2000; Microsoft Switzerland Ltd. Liab. Co., 
Wallisellen, Switzerland). Baseline questionnaire at enrollment and annual follow-up 
questionnaires included demographic data, IBD subtype and diagnosis, disease localization 
according to international guidelines, prior and current medications as well as past and present 
EIM. Electronic and written charts of those patients, who reported past or present EIM, were 
additionally reviewed by clinical experts in order to extract exact appearance of EIM in relation 
to IBD diagnosis, EIM subtype, chronological order of appearance of multiple EIM and 
evolution of EIM in response to anti-TNF treatment. All 329 patients in the PSIBDCS were 
eligible. For detailed analysis, only those patients with one or more EIM were included. For a 
comparison between the pediatric and adult population, data from the SIBDCS was used 
according to a recent study conducted by Vavricka et al (7). 
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Statistical analysis 
For all statistical analyses, IBM software SPSS version 23.0.0 (2014 SPSS Science, Inc., 
Armonk NY) was used. Metric data are shown as medians with their total range. Categorical data 
are depicted as percentage of the group total. Comparison between categorical variables was 
performed by using Chi-square test or Fisher`s exact test, if sample size was low (n<10). A two 
sided p-value of <0.05 was considered statistically significant. The association between potential 
predicting factors and positive anti-TNF outcome was analyzed by means of logistic regression.  
 
RESULTS 
Patient demographics  
Of the 329 pediatric IBD patients included in the study, 173 (52.6%) had CD and 156 (47.4%) 
had UC/IBD-U, 148 patients were female (45.0%). Median age at enrollment was 14 years (0-
17) and median age at IBD diagnosis was 12 years (0-16). The patients had been suffering from 
IBD for a median of 3 years (0-16). Patient demographics according to IBD subtype (including 
disease localization and received medications) are summarized in Table 1. Of the 329 patients, 
55 presented with one or more EIM (16.7%). The characteristics of those patients are depicted in 
Table 2.  
 
Frequency and types of EIM 
Of the 55 patients with at least one EIM, 39 patients had CD (39/55, 70.9%), 12 patients UC 
(12/55, 21.8%) and 4 patients IBD-U (4/55, 7.3%) as their underlying condition. Of these 55 
EIM patients, 39 (70.9%), 12 (21.8%), three (5.5%) and one patient (1.8%) reported one, two, 
three and four EIM, respectively. At IBD onset, presence of EIM was more frequent than in the 
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adult population (28/329, 8.5% vs. 62/1249, 5.0%, p=0.014). EIM were more frequently 
observed in CD patients (39/173, 22.5%) when compared to UC/IBD-U patients (16/156, 10.3%, 
p=0.003). The most prevalent EIM were peripheral arthritis (26/329, 7.9%) and aphthous 
stomatitis (24/329, 7.3%), followed by uveitis (6/329, 1.8%), EN (5/329, 1.5%), axial 
arthropathy (5/329, 1.5%), psoriasis (4/329, 1.2%), PSC (4/329, 1.2%) and PG (2/329, 0.6%). 
Peripheral arthritis, axial athropathy and EN were less frequently encountered among pediatric 
IBD patients compared to adult patients (7.9 vs. 20.5%, p<0.001, 1.5 vs. 4.8%, p=0.008 and 1.5 
vs. 3.7%, p=0.048). Frequency of other EIM were comparable between the two populations. For 
a detailed overview see Figure 1. While 27.6% of all EIM (21/76) appeared before the diagnosis 
of IBD, the majority of EIM appeared once IBD diagnosis was established (42/76, 55.3%). The 
remaining proportion of EIM (12/76, 15.8%) was first observed at the time of establishment of 
IBD diagnosis. Data from 1 EIM was missing. So, at the time of IBD diagnosis, 28 of the 55 
patients presented with a total of 33 EIM (observed before or at the time of IBD diagnosis); 
Aphthous stomatitis and peripheral arthritis were again the most frequently observed EIM 
(15/28, 53.6% and 10/28, 35.7%, respectively). For a synopsis over the phenotypic features at 
IBD diagnosis see Supplemental Digital Content 1, Table 1 (http://links.lww.com/MPG/A827). 
Details about frequency and type of EIM according to IBD subtype are shown in Table 2.  
 
Distribution of different EIM according to their chronological appearance 
Aphthous stomatitis was the most prevalent EIM (21/55, 38.2%), which appeared as first EIM 
(n=55), followed by peripheral arthritis (19/55, 34.5%) and uveitis (4/55, 7.3%). If the patient 
was diagnosed with a second EIM (n=16), peripheral arthritis (5/16, 31.3%), EN (3/16, 18.8%), 
aphthous stomatitis (2/16, 12.5%) and axial arthropathy (2/16, 12.5%) were most frequent. In 
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those patients presenting with a third EIM (n=4), occurrence of the following EIM were 
reported: peripheral arthritis (1/4, 25.0%), uveitis (1/4, 25.0%), aphthous stomatitis (1/4, 25.0%) 
and psoriasis (1/4, 25.0%).  Median time between IBD diagnosis and occurrence of first EIM 
was 1 month (range -37.5 – 149.0). Figure 2 illustrates the chronological order of appearance of 
each individual EIM in relation to the time of IBD diagnosis (in months). Peripheral arthritis 
appeared before IBD diagnosis in 28.0% (7/25, exact appearance in 1 case unknown), uveitis in 
16.7% (1/6), EN in 20% (1/5), axial arthropathy in 40.0% (2/5) and aphthous stomatitis in 29.2% 
(7/24). All cases of psoriasis (4/4, 100%) and PG (2/2, 100%) appeared after IBD diagnosis was 
established. In addition, peripheral arthritis (64.0 vs. 28.0%, p=0.011) and uveitis (83.3 vs. 
16.7%, p=0.021) were significantly more likely to appear after diagnosis of IBD than before 
establishment of IBD diagnosis. Median lag of time of appearance prior to IBD diagnosis in the 
group of patients in whom EIM preceded IBD diagnosis was -5.0 months (range -37.5 to -0.4) 
 
Type of anti-TNF treatment and treated EIM 
Anti-TNF therapy was initiated in 31 of the 55 patients with EIM (56.4%). Most of them were 
treated with a single anti-TNF agent (23/31, 74.2%), while five patients were treated with two 
and three patients with three different anti-TNF agents (5/31, 16.1% and 3/31, 9.7%, 
respectively). So, a total of 42 treatment courses were initiated. In 78.6% (33/42), anti-TNF 
treatment was started for the purpose of treating underlying IBD activity. In 3 cases (3/42, 7.1%), 
anti-TNF was solely initiated for the purpose of treating EIM; Infliximab was started for 
peripheral arthritis (n=1) and axial arthropathy (n=1), adalimumab was initiated for peripheral 
arthritis (n=1). In five cases (5/42, 11.9%), anti-TNF was started for the purpose of treating both 
intestinal disease activity and EIM. In 1 case, exact indication for anti-TNF treatment was not 
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known. IBD patients presenting with EIM were more likely to be treated with anti-TNF 
compared to those without EIM (31/55, 56.4% vs. 96/274, 35.0%, p=0.003). The most frequently 
treated EIM were peripheral arthritis (16/42, 38.1%) and aphthous stomatitis (13/42, 31.0%), 
followed by axial arthropathy, uveitis and EN. For details see Table 3. Under anti-TNF 
treatment, 23 EIM appeared in 19 of the 31 treated patients (19/31, 61.3%). Among those 23 
EIM, peripheral arthritis (6 cases) and aphthous stomatitis (5 cases) were the most frequently 
reported. Three cases of psoriasis occurred under anti-TNF therapy, which can be considered as 
anti-TNF induced psoriasiform skin lesions. Further reported EIM, which appeared under anti-
TNF, were: uveitis (2 cases), PG (1 case), EN (2 cases) and axial arthropathy (1 case). In 
remaining three cases, the exact EIM subtype was unknown. 
 
Clinical evolution of EIM under anti-TNF treatment 
Data on clinical outcome of anti-TNF treatment was available for 37 of the 53 treated EIM 
(69.8%). In the majority, EIM showed improvement (17/37, 45.9%) or stable disease course 
(13/37, 35.1%), while clinical worsening was observed in only 7 cases (7/37, 18.9%). Peripheral 
arthritis and uveitis showed good clinical response rates to anti-TNF (61.5% and 66.7%, 
respectively), while those of PG, axial arthropathy, aphthous stomatitis and EN were ≤50% 
(50.0%, 50.0%, 33.3%, and 33.3%, respectively, Table 3). In a multivariate regression model 
adjusted for age and gender, appearance of EIM before IBD diagnosis was the only independent 
predictor for positive anti-TNF outcome (OR 9.70, 95% confidence interval 1.04-90.04, 
p=0.046). Details about the multivariate analysis can be found in the Supplemental Digital 
Content 2, Table 2 (http://links.lww.com/MPG/A828). 
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DISCUSSION 
In this analysis of the Pediatric Swiss IBD cohort study, we report on frequency and 
chronological order of appearance of extraintestinal manifestations, the use of anti-TNF agents, 
and the disease course under such therapy. EIM are common in pediatric patients with IBD and 
can appear in nearly 30% before IBD diagnosis is established. Anti-TNF are used frequently in 
those patients, although they are started for the purpose of treating EIM in only a minority. Type 
of EIM might affect anti-TNF outcome. Best response rates were seen for peripheral arthritis and 
uveitis. 
 
EIM were frequently encountered in pediatric IBD, the prevalence of 16.7% is comparable to 
prior data from Guariso et al (27). However, prevalence is considerably lower compared to the 
studies conducted by Dotson (30) and Heyman (26), which is mainly due to our more stringent 
definition of EIM, as we did not include non-specific arthralgia or other non-specific EIM such 
as anemia, hepatitis, pancreatitis or osteoporosis. In accordance to the findings of Guariso et al., 
presence of EIM at IBD onset was more frequent in the PSIBDCS compared to the adult 
population (8.5 vs. 5%), although difference was considerably smaller (14.3 vs. 7.3% in the 
study of Guariso) (27). Our numbers fit well within the range of 6-47% EIM prevalence typically 
reported (2, 4-6, 13, 31). Our finding that EIM were more frequently observed in CD compared 
to UC patients is consistent with prior studies from adult IBD cohorts (7, 8, 13). Moreover, the 
order of frequency is consistent throughout the adult EIM literature and our data are in 
agreement with published observations: Musculoskeletal symptoms (such as peripheral arthritis) 
are followed by stomatitis, ophthalmological problems (such as uveitis), and skin changes (8, 
26). Although the proportion of patients presenting with arthritis is higher among adult patients, 
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order of frequency of EIM did not show a difference between the adult and pediatric IBD 
patients. EIM were more likely to appear after IBD diagnosis compared to before. Nonetheless, a 
non-negligible proportion (up to 30%) of EIM appeared before IBD diagnosis was established. 
Axial arthropathy appeared before IBD diagnosis in an even higher proportion. Both findings are 
consistent with data from adult cohorts (7). So, clinicians should be aware of those EIM 
manifesting before intestinal symptoms in order to decrease the diagnostic delay. Our group has 
recently shown that such diagnostic delay is a concern (32) and that a delayed diagnosis is 
associated with a complicated disease course in CD patients (33). Appearance of more than one 
EIM was observed only infrequently. Thus, the fact, that one EIM seems to increase the 
susceptibility of developing other EIM does not seem to be true for pediatric patients (34) or 
latency between first and second EIM may have been too long to allow detection in children. 
Taken together, our data suggest that epidemiology and presentation of EIM is quite similar in 
the pediatric and the adult population, suggesting similar disease mechanisms. 
 
Anti-TNF were frequently used in pediatric patients with EIM. However, those agents were 
specifically initiated for treating EIM in only a minority. So, clinical practice seems to be in 
accordance to current guidelines, which recommend to treat underlying IBD activity rather than 
EIM themselves. Nonetheless, patients with EIM were significantly more often treated with anti-
TNF than those without EIM. The latter may be explained by prior findings from Vavricka et al. 
who showed that active disease is an independent risk factor for EIM in both UC and CD (8). 
Upon anti-TNF treatment, EIM showed overall response rates of nearly 50%, which depended on 
the underlying EIM with the best rates for peripheral arthritis and uveitis. While direct 
comparisons are not possible, higher response rates to anti-TNF treatment were described in the 
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adult population (71.8%) (35). New onset of EIM under anti-TNF treatment also has been 
encountered in our study. Diagnosis of psoriasis was established in 3 of the 31 anti-TNF treated 
patients, which can be interpreted retrospectively as anti-TNF induced psoriasiform skin lesion. 
Prevalence seems to be in accordance to that reported in the literature (36).  
 
Our study has several strengths and some limitations as well. So far, it is one of the largest 
analyses of collected data evaluating frequency and occurrence of EIM in the pediatric IBD 
population. Furthermore, a detailed chart review revealed information about chronological 
appearance of EIM according to EIM subtype, the use of anti-TNF treatment and clinical 
response to such a therapy. The combination of physician and patient based questionnaire might 
have prevented the underreporting of EIM in our study population. However, we used an 
uncontrolled, non-interventional study design, which limits interpretation of anti-TNF treatment 
outcome. With annual follow-up visits, important details occurring during this period of time 
might have been missed. However, this potential recall bias has been limited by the combination 
of physician- and patient-based questionnaires. Given the fact that the Pediatric Swiss IBD 
cohort is not strictly population based, a selection bias may be present. For instance, patients 
included by private practices and community hospitals were underrepresented compared with 
those patients included by university hospitals (30.9% of the patients presenting with EIM were 
recruited in private practices or community hospitals, while 69.1% were recruited by physicians 
working in a university hospital). A clear limitation of our analysis is that – at the time of data 
analysis – we did not clearly differentiate between psoriasis and psoriasiform anti-TNF 
associated skin lesions, which is an increasingly reported phenomenon (36). However, with 4 
cases, prevalence of psoriasis was extremely low, and 3 out of 4 cases can be retrospectively 
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considered as anti-TNF induced as they presented under anti-TNF treatment for the first time. 
Due to the retrospective nature of the study, a non-negligible proportion of patients received 
concomitant immunomodulators and/or steroids in addition to anti-TNF, which may have led to 
an overestimation of anti-TNF response rates. 
 
In summary, in a cohort of pediatric IBD patients, EIM were frequently encountered. In up to 
30% of patients, EIM appeared before IBD was diagnosed. Knowledge of these findings may 
result in increased awareness of underlying IBD, thereby decreasing potential diagnostic delay. 
Anti- TNF for the treatment of certain EIMs is effective although a substantial proportion of new 
EIMs might present despite ongoing anti-TNF therapy. However randomized controlled trials are 
needed in the pediatric IBD population. 
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  CD patients UC/IBD‐U patients All IBD patients
Number of patients  173 (52.6)  156 (47.4)  329 (100.0) 
Gender 
  Male 
  Female 
 
104 (60.1) 
69 (39.9) 
 
77 (49.4) 
79 (50.6) 
 
181 (55.0) 
148 (45.0) 
Age at diagnosis in years 
(median, IQR, range) 
12, 10‐14 
0‐16 
11, 7‐14 
0‐16 
12, 9‐14 
0‐16 
Age at enrollment [years] 
(median, IQR, range) 
14, 12‐15 
0‐17 
13, 11‐15 
0‐17 
14, 11‐15 
0‐17 
Age at latest follow‐up [years] 
(median, IQR, range) 
16, 14‐17 
0‐18 
16, 13‐17 
0‐18
16, 13‐17 
0‐18 
Disease duration [years] 
(median, IQR, range) 
3, 2‐5 
0‐15 
3, 1‐6 
0‐16 
3, 2‐5 
0‐16 
Diagnostic Delay [months] 
(median, IQR, range) 
4.1, 2.0‐8.1 
0‐83.2 
3.0, 1.0‐6.1 
0‐59.9 
3.1, 2.0‐7.1 
0‐83.2 
Initial Disease Location [CD] 
  L1 
  L2 
  L3 
  L4 only 
  Unknown/unclear 
 
23 (13.3) 
22 (12.7) 
119 (68.8) 
3 (1.7) 
6 (3.5) 
 
‐ 
‐ 
‐ 
‐ 
‐ 
 
Initial Disease Location [UC] 
  E1 
  E2 
  E3/E4 
  Unknown/unclear 
 
‐ 
‐ 
‐ 
‐ 
 
13 (8.3) 
28 (18.0) 
104 (66.7) 
11 (7.0) 
 
Fistulas 
  Perianal Fistula 
  Other Fistula 
 
24 (13.9) 
12 (6.9) 
 
‐ 
‐ 
 
Stenosis 
  Any stenosis 
 
22 (12.7) 
 
‐ 
 
Medication Ever Received 
  5‐ASA 
  Antibiotics 
  Steroids 
  Immunomodulators 
  Anti‐TNF 
 
84 (48.6) 
64 (37.0) 
140 (80.9) 
155 (89.6) 
87 (50.3) 
 
149 (95.5) 
46 (29.5) 
117 (75.0) 
101 (64.7) 
40 (25.6) 
 
233 (70.8) 
110 (33.4) 
257 (78.1) 
256 (77.8) 
127 (38.6) 
TABLE 1: Patient demographics of the Pediatric Cohort 
  
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  All n=55 (%)  UC n=12 (%) CD n=39 (%) IBD‐U n=4 (%)
Sex  
‐ male 
‐ female 
 
34 (61.8) 
21 (38.2) 
 
6 (50.0) 
6 (50.0)
 
26 (66.7) 
13 (33.3)
 
2 (50.0) 
2 (50.0) 
Age at IBD Diagnosis in 
years 
11.3 (0.8‐15.7)  9.5 (2.5‐15.5)  11.5 (0.8‐15.4)  14.0 (12.4‐15.7) 
Number of EIM 
‐ 1 
‐ 2 
‐ 3 
‐ 4 
 
39 (70.9) 
12 (21.8) 
3 (5.5) 
1 (1.8) 
 
6 (50.0) 
6 (50.0) 
0 (0.0) 
0 (0.0) 
 
29 (74.4) 
6 (15.4) 
3 (7.7) 
1 (2.6) 
 
4 (100.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
Age at first EIM in years  12.8 (3.1‐17.4)  11.5 (3.8‐15.4)  13.1 (3.1‐17.4)  13.0 (9.3‐14.9) 
Time from IBD to first 
EIM in months 
1.0 (‐37.5‐149.0)  5.0(‐26.0‐149.0)  1.5 (‐28.0‐102.0)  ‐18.0 (‐37.4‐1.0) 
Type of EIM 
‐ Arthritis 
‐ Uveitis 
‐ PG 
‐ EN 
‐ Stomatitis 
‐ AS 
‐ PSC 
‐ Psoriasis 
 
26 (47.3) 
6 (10.9) 
2 (3.6) 
5 (9.1) 
24 (43.6) 
5 (9.1) 
4 (7.3) 
4 (7.3) 
 
6 (50.0) 
0 (0.0) 
1 (8.3) 
1 (8.3) 
5 (41.7) 
2 (16.7) 
3 (25.0) 
0 (0.0) 
 
19 (48.7) 
5 (12.8) 
1 (2.6) 
4 (10.3) 
18 (46.2) 
3 (7.7) 
0 (0.0) 
4 (10.3) 
 
1 (25.0) 
1 (25.0) 
0 (0.0) 
0 (0.0) 
1 (25.0) 
0 (0.0) 
1 (25.0) 
0 (0.0) 
Occurrence of EIM 
‐ Before 
‐ Concomitant 
‐ After 
‐ Unknown 
n=76 
21 (27.6) 
12 (15.8) 
42 (55.3) 
1 (1.3) 
n=18 
4 (22.2) 
3 (16.7) 
11 (61.1) 
0 (0.0) 
n=54 
14 (25.9) 
9 (16.7) 
30 (55.6) 
1 (1.9) 
n=4 
3 (75.0) 
0 (0.0) 
1 (25.0) 
0 (0.0) 
TABLE 2: Demographics and  frequency and type of EIM according to  IBD subtype. AS, axial 
arthropathy; EN, erythema nodosum; PG, pyoderma gangrenosum; PSC, primary sclerosing 
cholangitis 

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  All anti‐TNF 
(n=42) 
Indication for anti‐TNF 
‐ IBD 
‐ EIM 
‐ Both 
‐ Unknown 
 
33 (78.6) 
3 (7.1) 
5 (11.9) 
1 (2.4) 
Treated EIM 
‐ Arthritis 
‐ Uveitis 
‐ PG 
‐ EN 
‐ Stomatitis 
‐ AS 
‐ PSC  
‐  (Unknown type) 
 
16 (38.1) 
4 (9.5) 
3 (7.1) 
4 (9.5) 
13 (31.0) 
5 (11.9) 
0 (0.0) 
 (8) 
Outcome of treated EIM 
‐ Improvement 
‐ Stable disease 
‐ Worsening 
‐ (unknown outcome) 
n=37 
17 (45.9) 
13 (35.1) 
7 (18.9) 
(16) 
Anti‐TNF response rates 
‐ Arthritis 
‐ Uveitis 
‐ PG 
‐ EN 
‐ Stomatitis 
‐ AS 
 
61.5% (8/13) 
66.7% (2/3) 
50.0% (1/2) 
33.3% (1/3) 
33.3% (3/9) 
50.0% (2/4)
 
TABLE 3: Anti‐TNF treatment. AS, axial arthropathy; EN, erythema nodosum; PG, pyoderma 
gangrenosum; PSC, primary sclerosing cholangitis 
  
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